Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Occult hepatitis B is defined by the presence of hepatitis B virus (HBV) DNA in the absence of hepatitis B surface antigen (HBsAg). Occult HBV is associated with the development of hepatocellular carcinoma, reactivation during immune suppression, and virus transmission. Viral mutations contribute significantly to the occult HBV phenotype. Mutations in the 'a' determinant of HBsAg are of particular interest, as these mutations are associated with immune escape, vaccine escape and diagnostic failure. We examined the effects of selected occult HBV-associated mutations identified in a population of HIV-positive South Africans on HBsAg production in vitro. Mutations were inserted into two different chronic HBV backbones and transfected into a hepatocyte-derived cell line. HBsAg levels were quantified by enzyme-linked immunosorbent assay (ELISA), while the detectability of mutant HBsAg was determined using an HA-tagged HBsAg expression system. Of the seven mutations analysed, four (S132P, C138Y, N146D and C147Y) resulted in decreased HBsAg expression in one viral background but not in the second viral background. One mutation (N146D) led to a decrease in HBsAg detected as compared to HA-tag, indicating that this mutation compromises the ability of the ELISA to detect HBsAg. The contribution of occult-associated mutations to the HBsAg-negative phenotype of occult HBV cannot be determined adequately by testing the effect of the mutation in a single viral background, and rigorous analysis of these mutations is required.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5756483PMC
http://dx.doi.org/10.1099/jgv.0.000469DOI Listing

Publication Analysis

Top Keywords

occult hbv
16
viral background
12
mutations
9
hbsag
9
'a' determinant
8
mutations associated
8
hiv-positive south
8
south africans
8
hbsag expression
8
occult
6

Similar Publications

Background & Aims: HBV integration profiles in the natural history of chronic HBV infection (CHB) have not been well-defined. Hence, we aimed to determine HBV integration profiles across different CHB phases.

Methods: We delineated integration profiles from liver biopsies of 55 patients in different CHB phases (3 HBsAg-positive/HBeAg-positive infection; 13 HBsAg-positive/HBeAg-positive hepatitis; 7 HBsAg-positive/HBeAg-negative infection; 12 HBsAg-positive/HBeAg-negative hepatitis; 10 HBsAg seroclearance; 10 occult HBV).

View Article and Find Full Text PDF

Background: The widespread use of TNF-α inhibitors (infliximab, adalimumab, golimumab, certolizumab pegol, and etanercept) in gastrointestinal, rheumatologic, and dermatologic disorders raises concerns about hepatitis B reactivation (HBVr). The exact risk remains unclear due to the variability in previous meta-analyses. This study aims to assess the effectiveness of antiviral prophylaxis in preventing HBV reactivation in patients on TNF-α therapy and to investigate the associated reactivation risk.

View Article and Find Full Text PDF

Background: Hepatitis B virus (HBV) infection is a major global health concern. Serological patterns such as "HBeAb + and HBcAb+" or "HBcAb + only" are typically markers, which may represent either resolved infection or potential occult HBV infection (OBI) with risk of vertical transmission. But OBI in these subgroups of pregnant women in Northwest China remains underreported.

View Article and Find Full Text PDF

Purpose: Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet counts due to the destruction of platelets by autoantibodies. The presence of hepatitis B core antibodies (anti-HBc) is a marker of previous or occult hepatitis B virus (HBV) infection, which may influence the clinical course and treatment outcomes in ITP patients.

Methods: This retrospective study investigated the impact of anti-HBc positivity on the clinical outcomes and response to treatment in ITP patients.

View Article and Find Full Text PDF

Background And Objectives: Universal mini-pool nucleic acid testing (NAT) for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and hepatitis B virus (HBV) in blood donations has been introduced in Taiwan since 2013. This study aimed to evaluate changes in donors' infection profiles and residual risks of transfusion-transmitted infections (TTIs) for these viruses after NAT implementation.

Materials And Methods: Donations from 15 January 2013 to December 2023 were included in this study.

View Article and Find Full Text PDF